DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens
The graft-versus-leukemia effect of allogeneic stem-cell transplantation is believed to be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells. For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease. To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable. However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity. An alternative approach is to prime specific CTL responses in vivo by vaccination. Clearly, donor vaccination must be safe and specific. We have developed DNA fusion vaccines able to induce high levels of epitope-specific CTL using linked CD4(+) T-cell help. The vaccines incorporate a domain of tetanus toxin (DOM) fused to a sequence encoding a candidate MHC class I binding peptide. This design generates antitumor CD8(+) T-cell responses and protective immunity in preclinical models. For clinical application, we constructed vaccines encoding HLA-A*0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A*0201-transgenic mice. Priming induced epitope-specific, IFNgamma-producing CD8(+) T cells with cytotoxic function boosted to high levels with electroporation. Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2. High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction. These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
5436-5442
Rice, Jason
d58d4fcd-8dc0-4599-bf96-62323d579227
Dunn, Stuart
e6fd3eb2-4487-45ed-b9d7-948febd5b7ea
Piper, Karen
9e8b2383-59f5-42ac-8291-c8411df68713
Buchan, Sarah L.
9ade187d-f127-45de-ad90-9d544d64718a
Moss, Paul A.
a4623127-aaa7-4e69-b236-b75b70528bba
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
15 May 2006
Rice, Jason
d58d4fcd-8dc0-4599-bf96-62323d579227
Dunn, Stuart
e6fd3eb2-4487-45ed-b9d7-948febd5b7ea
Piper, Karen
9e8b2383-59f5-42ac-8291-c8411df68713
Buchan, Sarah L.
9ade187d-f127-45de-ad90-9d544d64718a
Moss, Paul A.
a4623127-aaa7-4e69-b236-b75b70528bba
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Rice, Jason, Dunn, Stuart, Piper, Karen, Buchan, Sarah L., Moss, Paul A. and Stevenson, Freda K.
(2006)
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Cancer Research, 66 (10), .
(doi:10.1158/0008-5472.CAN-05-3130).
Abstract
The graft-versus-leukemia effect of allogeneic stem-cell transplantation is believed to be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells. For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease. To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable. However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity. An alternative approach is to prime specific CTL responses in vivo by vaccination. Clearly, donor vaccination must be safe and specific. We have developed DNA fusion vaccines able to induce high levels of epitope-specific CTL using linked CD4(+) T-cell help. The vaccines incorporate a domain of tetanus toxin (DOM) fused to a sequence encoding a candidate MHC class I binding peptide. This design generates antitumor CD8(+) T-cell responses and protective immunity in preclinical models. For clinical application, we constructed vaccines encoding HLA-A*0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A*0201-transgenic mice. Priming induced epitope-specific, IFNgamma-producing CD8(+) T cells with cytotoxic function boosted to high levels with electroporation. Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2. High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction. These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
Text
5436.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: 15 May 2006
Identifiers
Local EPrints ID: 44615
URI: http://eprints.soton.ac.uk/id/eprint/44615
ISSN: 0008-5472
PURE UUID: bf3a536b-3099-4a1d-b0ba-5ffbd3d7511f
Catalogue record
Date deposited: 06 Mar 2007
Last modified: 16 Mar 2024 02:54
Export record
Altmetrics
Contributors
Author:
Jason Rice
Author:
Stuart Dunn
Author:
Karen Piper
Author:
Sarah L. Buchan
Author:
Paul A. Moss
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics